A Phase I/II Study of Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Haploidentical and Cord Blood Stem Cell Transplantation
Latest Information Update: 02 Aug 2023
At a glance
- Drugs Interleukin-7 (Primary) ; Interleukin-7 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 03 Mar 2023 Status changed from recruiting to completed.
- 26 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 26 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.